This article is more than 5 years old. Information may no longer be current.

TEVAR with stent graft system effective at 1 year

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ali Azizzadeh

A thoracic stent graft system was safe and effective at 1 year in patients requiring thoracic endovascular aortic repair, according to new data presented at VEITHSymposium.

In the cohort of 89 patients (mean age, 71 years; 40% women) treated with the system (Valiant Navion, Medtronic) for thoracic aortic aneurysms or penetrating aortic ulcers, the 1-year rate of freedom from secondary procedures was 94.8%, Ali Azizzadeh, MD, director of vascular surgery, vice chair of surgery and associate director of the Heart Institute at Cedars-Sinai, said during a presentation.

At 1 year, 4% of patients had a type Ib endoleak and 2.7% of patients had a type II endoleak, he said, noting there were no new type Ia endoleaks beyond 30 days.

In addition, 97.4% of patients had a stable or decreasing aneurysm sac at 1 year, he said.

“The design enhancements of Valiant Navion demonstrate positive clinical performance,” Azizzadeh said during the presentation. “One-year clinical results are encouraging. There were no access or deployment failures in tortuous anatomy.”

The mean duration of the procedure was 88.6 minutes and mean total fluoroscopy time was 12.1 minutes. Percutaneous access was used in 49% of patients.

Access artery tortuosity was severe in 73.7% of patients, whereas thoracic aorta tortuosity was high in 86.5% of patients, Azizzadeh said, noting that intended landing areas were calcific in 60% of patients and thrombus in 15.2% of patients.

The investigational device exemption study was used to support regulatory approval of the device, Azizzadeh said, noting FDA approval was granted in October 2018 and a CE mark was granted in November 2018. – by Erik Swain

Reference:

Azizzadeh A, et al. Session 58. New or updated endovascular devices for treating descending aortic lesions (TEVAR) and TAAAs. Presented at: VEITHSymposium; Nov. 19-23, 2019; New York.

Disclosures: The study was funded by Medtronic. Azizzadeh reports he received research funding and honoraria from and consults for Medtronic and W.L. Gore and Associates.